Status:
COMPLETED
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
Lead Sponsor:
Nektar Therapeutics
Conditions:
Malignant Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression si...
Eligibility Criteria
Inclusion
- Inclusion:
- Received prior treatment with NKTR-102
- Free of disease progression since receiving NKTR-102
- Adequate bone marrow and organ function
- Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102
- Agree to use adequate contraception
- Exclusion:
- Treatment with other anti-cancer therapy between the last dose of NKTR-102 in the prior study and before first dose of NKTR-102 in the extension study
- A toxicity that requires a 3rd dose reduction after taking NKTR-102 or are scheduled to receive a dose \< 70 mg/m2 upon entry into this study
- Pregnancy or lactation
Exclusion
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01457118
Start Date
October 1 2011
End Date
November 1 2017
Last Update
July 12 2021
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigator Site - Los Angeles
Los Angeles, California, United States, 90033
2
Investigator Site - San Francisco
San Francisco, California, United States, 94143
3
Investigator Site - Whittier
Whittier, California, United States, 90603
4
Investigator Site - Minneapolis
Minneapolis, Minnesota, United States, 55455